Table 3.
Transitioning Characteristics of Transgender Women According to HIV Serostatus—Transcendendo Cohort, Rio de Janeiro, Brazil, 2015–2017
| Transitioning characteristics | Total N=322 | HIV-uninfected N=148 | HIV-infected N=174 | p |
|---|---|---|---|---|
| Age of gender perceptiona | ||||
| ≤7 | 112 (34.8) | 56 (37.8) | 56 (32.2) | 0.254 |
| 8–10 | 93 (28.9) | 39 (26.4) | 54 (31.0) | |
| 11–13 | 66 (20.5) | 29 (19.6) | 37 (21.3) | |
| ≥14 | 47 (14.6) | 24 (16.2) | 23 (13.2) | |
| Missing | 4 (1.2) | 0 (0.0) | 4 (2.3) | |
| Age of gender transitiona | ||||
| <14 | 59 (18.3) | 24 (16.2) | 35 (20.1) | 0.151 |
| 14–17 | 148 (46.0) | 63 (42.6) | 85 (48.9) | |
| ≥18 | 114 (35.4) | 61 (41.2) | 53 (30.5) | |
| Missing | 1 (0.3) | 0 (0.0) | 1 (0.6) | |
| Ever performed gender affirmation proceduresb | 132 (41.0) | 59 (39.9) | 73 (42.0) | 0.790 |
| Ever had sex reassignment surgeryb | 19 (5.9) | 15 (10.1) | 4 (2.3) | 0.006 |
| Ever injected fillers | 158 (49.1) | 57 (38.5) | 101 (58.0) | <0.001 |
| Hormone use | ||||
| Current | 158 (49.1) | 88 (59.5) | 70 (40.2) | 0.002 |
| Past | 147 (45.7) | 52 (35.1) | 95 (54.6) | |
| Never | 16 (5.0) | 8 (5.4) | 8 (4.6) | |
| Missing | 1 (0.3) | 0 (0.0) | 1 (0.6) | |
| Medically guided hormone use | 0.014 | |||
| Never | 240 (78.7) | 100 (71.4) | 140 (84.8) | |
| Current | 29 (9.5) | 21 (15.0) | 8 (4.8) | |
| Past | 19 (6.2) | 10 (7.1) | 9 (5.5) | |
| Missing | 17 (5.6) | 9 (6.4) | 8 (4.8) | |
| Current use of ethinylestradiolc | 59 (37.3) | 35 (39.8) | 24 (34.3) | 0.587 |
| Current use of IM estradiol plus progestagenc | 91 (57.6) | 45 (51.1) | 46 (65.7) | 0.093 |
| Current use of estradiol plus antiandrogenc | 22 (13.9) | 16 (18.2) | 6 (8.6) | 0.133 |
| Total testosteronea,c | ||||
| At target level | 89 (56.3) | 53 (60.2) | 36 (51.4) | 0.221 |
| Above target level | 64 (40.5) | 34 (38.6) | 30 (42.9) | |
| Missing | 5 (3.2) | 1 (1.1) | 4 (5.7) | |
| Estradiola,c | ||||
| Below target level | 80 (50.6) | 47 (53.4) | 33 (47.1) | 0.433 |
| At target level | 47 (29.7) | 26 (29.5) | 21 (30.0) | |
| Above target level | 26 (16.5) | 14 (15.9) | 12 (17.1) | |
| Missing | 5 (3.2) | 1 (1.1) | 4 (5.7) | |
a
Continuous variables were reclassified as categorical.
b
Breast augmentation, facial feminization, tracheal shave, or sex reassignment surgery (vaginoplasty, penectomy, and oorchiectomy).
c
Evaluated to trans women currently using hormones (n=158).
IM, intramuscular.